<DOC>
	<DOC>NCT01145755</DOC>
	<brief_summary>This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.</brief_summary>
	<brief_title>6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, parallel Group Study to Assess the Efficacy and Safety of AZD2066 after 6 weeks of treatment in Patients with Major Depressive Disorder - D0475C00020.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Provision of signed, written, and dated Informed Consent Documented primary clinical diagnosis of Major Depressive Disorder Patients with a secondary psychiatric disorder including bipolar disorder, psychotic disorders (i.e. schizophrenia, schizoaffective disorder, depression with psychotic features), GAD and social anxiety disorder Patients whose current episode of depression started less than 4 weeks before enrollment History of inadequate response of antidepressants during current depressive episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Depression</keyword>
</DOC>